Literature DB >> 10663342

Bone mineral density in patients with treated Addison's disease.

G D Braatvedt1, M Joyce, M Evans, J Clearwater, I R Reid.   

Abstract

Some studies have reported low bone mineral density (BMD) in patients with Addison's disease, whereas others have found BMD to be normal. It is possible that over-replacement of corticosteroids and adrenal androgen deficiency may contribute to a reduction in BMD in these patients. The aims of this study were to examine BMD using dual-energy X-ray absorptiometry in patients with treated Addison's disease at multiple skeletal sites and to investigate the relationships between these measurements and corticosteroid dose. Nineteen men, 3 premenopausal and 7 postmenopausal women with Addison's disease were studied and data from these patients were analyzed separately and as a group. The mean SEM age and duration of Addison's disease of the men were 44 +/- 3.8 years and 15 +/- 2.2 years, in the premenopausal women 40 +/- 2 years and 5 +/- 2.4 years, and in the postmenopausal women 68 +/- 4 years and 20 +/- 5 years, respectively. Eight men were unexpectedly hypogonadal (serum testosterone <13 nmol/l). BMD was expressed as a percent of values in normal controls (n = 418) adjusted for age, sex, ethnic origin, menopausal status and body weight. In the whole group (n = 29), mean BMD of the patients with Addison's disease was not different from normal at any site [mean (+/- SEM) lumbar spine 99.5% +/- 2.9%; femoral neck 99.3% +/- 2.5%; Ward's triangle 96.2% +/- 3.5%; trochanter 99.2% +/- 2.9%; radius 99.8% +/- 2.1%; total body 98.5% +/- 1.4%]. However, there was a wide range of bone densities, with some patients having a low BMD at multiple sites. Bone density was negatively correlated with current and cumulative corticosteroid dose per kilogram body weight and duration of Addison's disease. In conclusion, BMD in patients with Addison's disease is little different from normal, but may be lower in patients with disease of long duration and a high cumulative corticosteroid dose. Unexpected hypogonadism in men with Addison's disease is common.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10663342     DOI: 10.1007/s001980050251

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  7 in total

1.  Co-morbidities, management and clinical outcome of auto-immune Addison's disease.

Authors:  Lalantha Leelarathna; Louise Breen; James K Powrie; Stephen M Thomas; Rustom Guzder; Barbara McGowan; Paul V Carroll
Journal:  Endocrine       Date:  2010-07-03       Impact factor: 3.633

2.  Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison's disease on glucocorticoid and mineralocorticoid replacement therapy.

Authors:  Valentina Camozzi; Corrado Betterle; Anna Chiara Frigo; Veronica Zaccariotto; Martina Zaninotto; Erica De Caneva; Paola Lucato; Walter Gomiero; Silvia Garelli; Chiara Sabbadin; Monica Salvà; Miriam Dalla Costa; Marco Boscaro; Giovanni Luisetto
Journal:  Endocrine       Date:  2017-08-09       Impact factor: 3.633

Review 3.  Therapy of adrenal insufficiency: an update.

Authors:  Alberto Falorni; Viviana Minarelli; Silvia Morelli
Journal:  Endocrine       Date:  2012-11-21       Impact factor: 3.633

4.  The contribution of serum cortisone and glucocorticoid metabolites to detrimental bone health in patients receiving hydrocortisone therapy.

Authors:  Rosemary Dineen; Lucy-Ann Behan; Grainne Kelleher; Mark J Hannon; Jennifer J Brady; Bairbre Rogers; Brian G Keevil; William Tormey; Diarmuid Smith; Christopher J Thompson; Malachi J McKenna; Wiebke Arlt; Paul M Stewart; Amar Agha; Mark Sherlock
Journal:  BMC Endocr Disord       Date:  2020-10-10       Impact factor: 2.763

5.  Long-term outcomes of conventional and novel steroid replacement therapy on bone health in primary adrenal insufficiency.

Authors:  Valentina Guarnotta; Claudia Di Stefano; Carla Giordano
Journal:  Sci Rep       Date:  2022-08-02       Impact factor: 4.996

6.  9β Polymorphism of the glucocorticoid receptor gene appears to have limited impact in patients with Addison's disease.

Authors:  Ian Louis Ross; Collet Dandara; Marelize Swart; Miguel Lacerda; Desmond Schatz; Dirk Jacobus Blom
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

7.  Prednisolone is associated with a worse bone mineral density in primary adrenal insufficiency.

Authors:  Kathrin R Frey; Tina Kienitz; Julia Schulz; Manfred Ventz; Kathrin Zopf; Marcus Quinkler
Journal:  Endocr Connect       Date:  2018-05-02       Impact factor: 3.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.